DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unlocking of cancer cells.
DISCO Pharmaceuticals has raised $42.3M in total funding. The most recent round was Seed. The last funding was announced in December 2025.
DISCO Pharmaceuticals's investors include AbbVie, NRW.BANK, Sofinnova Partners, Panakes Partners, M Ventures.
DISCO Pharmaceuticals is headquartered in Cologne, Germany.
DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unlocking of cancer cells.
DISCO Pharmaceuticals is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"DISCO Pharmaceuticals — Funding & Investors." VCBacked, December 11, 2025, https://www.vcbacked.co/company/disco-pharmaceuticals. Accessed August 16, 2026.
VCBacked. (2025). DISCO Pharmaceuticals — Funding & Investors. Retrieved August 16, 2026, from https://www.vcbacked.co/company/disco-pharmaceuticals
{{cite web |title=DISCO Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/disco-pharmaceuticals |website=VCBacked |access-date=August 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated